
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a leader in the rapidly growing market for next-generation diagnostic tests that utilize comprehensive genomic information to improve the diagnosis of cancer and other diseases. Their tests, including Decipher, Afirma, Prosigna, and Decipher Bladder, have shown strong sales growth and potential for continued expansion. With the company's solid financial position and multiple upcoming presentations and trials, it is likely that their revenue and earnings will continue to grow, making it a potentially strong investment opportunity.
Bears say
Veracyte is a genomic diagnostics company that offers tests for multiple types of cancer. While the company has potential growth opportunities in the MRD market and ongoing studies for its TrueMRD platform, its financials do not currently support a strong outlook. The company has a history of generating revenue and testing volume growth, but its revenue per test is only increasing slightly and it is not yet profitable. Additionally, the company's reliance on its urology sales channel and the competition in the MRD market may limit its growth potential and profitability in the future.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares